242 related articles for article (PubMed ID: 22893205)
1. Genetics, inheritance and strategies for prevention in populations at high risk of colorectal cancer (CRC).
Burn J; Mathers J; Bishop DT
Recent Results Cancer Res; 2013; 191():157-83. PubMed ID: 22893205
[TBL] [Abstract][Full Text] [Related]
2. Chemoprevention of colorectal cancer: systematic review and economic evaluation.
Cooper K; Squires H; Carroll C; Papaioannou D; Booth A; Logan RF; Maguire C; Hind D; Tappenden P
Health Technol Assess; 2010 Jun; 14(32):1-206. PubMed ID: 20594533
[TBL] [Abstract][Full Text] [Related]
3. A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis.
Burn J; Bishop DT; Chapman PD; Elliott F; Bertario L; Dunlop MG; Eccles D; Ellis A; Evans DG; Fodde R; Maher ER; Möslein G; Vasen HF; Coaker J; Phillips RK; Bülow S; Mathers JC;
Cancer Prev Res (Phila); 2011 May; 4(5):655-65. PubMed ID: 21543343
[TBL] [Abstract][Full Text] [Related]
4. Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial.
Burn J; Sheth H; Elliott F; Reed L; Macrae F; Mecklin JP; Möslein G; McRonald FE; Bertario L; Evans DG; Gerdes AM; Ho JWC; Lindblom A; Morrison PJ; Rashbass J; Ramesar R; Seppälä T; Thomas HJW; Pylvänäinen K; Borthwick GM; Mathers JC; Bishop DT;
Lancet; 2020 Jun; 395(10240):1855-1863. PubMed ID: 32534647
[TBL] [Abstract][Full Text] [Related]
5. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial.
Burn J; Gerdes AM; Macrae F; Mecklin JP; Moeslein G; Olschwang S; Eccles D; Evans DG; Maher ER; Bertario L; Bisgaard ML; Dunlop MG; Ho JW; Hodgson SV; Lindblom A; Lubinski J; Morrison PJ; Murday V; Ramesar R; Side L; Scott RJ; Thomas HJ; Vasen HF; Barker G; Crawford G; Elliott F; Movahedi M; Pylvanainen K; Wijnen JT; Fodde R; Lynch HT; Mathers JC; Bishop DT;
Lancet; 2011 Dec; 378(9809):2081-7. PubMed ID: 22036019
[TBL] [Abstract][Full Text] [Related]
6. Chemoprevention in Lynch syndrome.
Burn J; Mathers JC; Bishop DT
Fam Cancer; 2013 Dec; 12(4):707-18. PubMed ID: 23880960
[TBL] [Abstract][Full Text] [Related]
7. Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial.
Ishikawa H; Mutoh M; Sato Y; Doyama H; Tajika M; Tanaka S; Horimatsu T; Takeuchi Y; Kashida H; Tashiro J; Ezoe Y; Nakajima T; Ikematsu H; Hori S; Suzuki S; Otani T; Takayama T; Ohda Y; Mure K; Wakabayashi K; Sakai T
Lancet Gastroenterol Hepatol; 2021 Jun; 6(6):474-481. PubMed ID: 33812492
[TBL] [Abstract][Full Text] [Related]
8. Long-term effect of resistant starch on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial.
Mathers JC; Movahedi M; Macrae F; Mecklin JP; Moeslein G; Olschwang S; Eccles D; Evans G; Maher ER; Bertario L; Bisgaard ML; Dunlop M; Ho JW; Hodgson S; Lindblom A; Lubinski J; Morrison PJ; Murday V; Ramesar R; Side L; Scott RJ; Thomas HJ; Vasen H; Gerdes AM; Barker G; Crawford G; Elliott F; Pylvanainen K; Wijnen J; Fodde R; Lynch H; Bishop DT; Burn J;
Lancet Oncol; 2012 Dec; 13(12):1242-9. PubMed ID: 23140761
[TBL] [Abstract][Full Text] [Related]
9. Cancer Prevention with Resistant Starch in Lynch Syndrome Patients in the CAPP2-Randomized Placebo Controlled Trial: Planned 10-Year Follow-up.
Mathers JC; Elliott F; Macrae F; Mecklin JP; Möslein G; McRonald FE; Bertario L; Evans DG; Gerdes AM; Ho JWC; Lindblom A; Morrison PJ; Rashbass J; Ramesar RS; Seppälä TT; Thomas HJW; Sheth HJ; Pylvänäinen K; Reed L; Borthwick GM; Bishop DT; Burn J;
Cancer Prev Res (Phila); 2022 Sep; 15(9):623-634. PubMed ID: 35878732
[TBL] [Abstract][Full Text] [Related]
10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
11. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome.
Burn J; Bishop DT; Mecklin JP; Macrae F; Möslein G; Olschwang S; Bisgaard ML; Ramesar R; Eccles D; Maher ER; Bertario L; Jarvinen HJ; Lindblom A; Evans DG; Lubinski J; Morrison PJ; Ho JW; Vasen HF; Side L; Thomas HJ; Scott RJ; Dunlop M; Barker G; Elliott F; Jass JR; Fodde R; Lynch HT; Mathers JC;
N Engl J Med; 2008 Dec; 359(24):2567-78. PubMed ID: 19073976
[TBL] [Abstract][Full Text] [Related]
12. Can resistant starch and/or aspirin prevent the development of colonic neoplasia? The Concerted Action Polyp Prevention (CAPP) 1 Study.
Mathers JC; Mickleburgh I; Chapman PC; Bishop DT; Burn J;
Proc Nutr Soc; 2003 Feb; 62(1):51-7. PubMed ID: 12740057
[TBL] [Abstract][Full Text] [Related]
13. Effect of chemoprevention by low-dose aspirin of new or recurrent colorectal adenomas in patients with Lynch syndrome (AAS-Lynch): study protocol for a multicenter, double-blind, placebo-controlled randomized controlled trial.
Soualy A; Deutsch D; Benallaoua M; Ait-Omar A; Mary F; Helfen S; Boubaya M; Levy V; Benamouzig R;
Trials; 2020 Sep; 21(1):764. PubMed ID: 32887653
[TBL] [Abstract][Full Text] [Related]
14. Preventive effects of low-dose aspirin on colorectal adenoma growth in patients with familial adenomatous polyposis: double-blind, randomized clinical trial.
Ishikawa H; Wakabayashi K; Suzuki S; Mutoh M; Hirata K; Nakamura T; Takeyama I; Kawano A; Gondo N; Abe T; Tokudome S; Goto C; Matsuura N; Sakai T
Cancer Med; 2013 Feb; 2(1):50-6. PubMed ID: 24133627
[TBL] [Abstract][Full Text] [Related]
15. Obesity, Aspirin, and Risk of Colorectal Cancer in Carriers of Hereditary Colorectal Cancer: A Prospective Investigation in the CAPP2 Study.
Movahedi M; Bishop DT; Macrae F; Mecklin JP; Moeslein G; Olschwang S; Eccles D; Evans DG; Maher ER; Bertario L; Bisgaard ML; Dunlop MG; Ho JW; Hodgson SV; Lindblom A; Lubinski J; Morrison PJ; Murday V; Ramesar RS; Side L; Scott RJ; Thomas HJ; Vasen HF; Burn J; Mathers JC
J Clin Oncol; 2015 Nov; 33(31):3591-7. PubMed ID: 26282643
[TBL] [Abstract][Full Text] [Related]
16. Cohorts with familial disposition for colon cancers in chemoprevention trials.
Burt RW
J Cell Biochem Suppl; 1996; 25():131-5. PubMed ID: 9027609
[TBL] [Abstract][Full Text] [Related]
17. Non steroidal anti-inflammatory drugs (NSAID) and Aspirin for preventing colorectal adenomas and carcinomas.
Asano TK; McLeod RS
Cochrane Database Syst Rev; 2004; 2004(2):CD004079. PubMed ID: 15106236
[TBL] [Abstract][Full Text] [Related]
18. A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): study protocol for a randomized controlled trial.
Hull MA; Sandell AC; Montgomery AA; Logan RF; Clifford GM; Rees CJ; Loadman PM; Whitham D
Trials; 2013 Jul; 14():237. PubMed ID: 23895505
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
[TBL] [Abstract][Full Text] [Related]
20. [Clinical management of adenomatous polyposis in patients with hereditary non-polyposis colorectal cancer and familial adenomatous polyposis].
Sheng JQ; Li SR; Yang XY; Zhang YH; Su H; Yu DL; Yan W; Geng HG
Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(8):526-9. PubMed ID: 16681880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
